1 / 20

Pharmaceuticals Limited

Pharmaceuticals Limited. India – CIS International Pharma Conference 3-5 th March 2006, Mumbai. Prashant Nagre Vice President – API Division. Top 10 destinations for Formulations Russia ranks 2nd. Top 10 destinations for Bulk Drugs Russia and CIS does not feature !.

benito
Download Presentation

Pharmaceuticals Limited

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceuticals Limited India – CIS International Pharma Conference 3-5th March 2006, Mumbai Prashant Nagre Vice President – API Division

  2. Top 10 destinations for Formulations Russia ranks 2nd Top 10 destinations for Bulk Drugs Russia and CIS does not feature ! What should be our OBJECTIVE? CIS should be among TOP 5 destinations

  3. IndianPharmaceuticalIndustry An Overview

  4. Industry Overview - • More than 8,000 to 9,000 manufacturing units • 300 Large and Medium sized companies account for more than 80% turnover • Performance • Turnover : $ 8.2 bn, growth 9% • Exports : $ 3.5 bn, growth 14.86% • API exports contribute 32%, growth 5% • Well established central & regional network of Regulatory authorities • Patent Act of 1970 helped the industry to grow rapidly INDIA IS SELF-SUFFICIENT TODAY

  5. Industry Overview • Infrastructure • Well developed, most of the pharmaceutical machinery locally made, Engineering and plant designs matching international standards • cGMP compliant manufacturing infrastructure • International approvals/accreditations • US FDA approvals - >80 units • UK MHRA • TGA, Australia • WHO-GMP • Talent Pool • Availability of educated manpower in abundance (Pharmacy, Engineering, Biotech and Science graduates) • Rich scientific talent & research capabilities

  6. Strengths : Active Pharmaceutical Ingredients Industry

  7. Strengths – Bulk Drug Industry • Reverse Engineering – • Process patents regime helped Indian industry to gain significant skills in Chemistry and process engineering • Quality – • comparable to best in world • Competitiveness – • Through efficiencies and lower cost of production in India • Understanding of regulatory requirements – • More than 35% of DMFs were filed from India in the US • State-of-the-art R&D infrastructure

  8. Strengths – Bulk Drug Industry • Introduction of product patents • Ability to be a partner in outsourcing and launch of new products • Product Portfolio • wide variety of drugs substances produced (Traditional antibiotics, New lifestyle categories like Cardiac, Respiratory and Vitamins, Anti HIV/ AIDS, CNS & Diabetic ) • Bird flu : Indian companies in the fore front

  9. Ranbaxy Labs Cipla Dr Reddy Labs GSK Nicholas Piramal Lupin Ltd Sun Pharma Cadila Healthcare Aurobindo Pharma Wockhardt Ltd Major Players : Bulk Drug Industry (Source: Compiled by Cygnus)

  10. Why to buy Indian Pharmaceuticals ?

  11. Why to buy Indian Pharmaceuticals ? Reliability Growth in exports mainly attributable to this reason

  12. Why to buy Indian Pharmaceuticals ? • Consolidated know-how in production process • High Product Quality • New regulatory compliance culture • Consistency in Quality • Strict Regulatory Compliance • Products meet most stringent GMP standards • Continuous technological innovation through R & D • Professionalism of sales and technical staff – “Global Service”

  13. Opportunities ex-India

  14. Opportunities • Exports • Bulk Drugs • Chemicals/Raw materials/Intermediates • Biotech & Biological Products • Joint Ventures with Indian Companies • Technology acquisitions

  15. Opportunities • Pellets/Directly compressible granules/times release products • Contract Research and Manufacturing (CRAMS) • Diversification in Destination – Russia & Ukraine constituted 78% of total bulk drug exports

  16. Vision for Indian Pharmaceutical Industry Padmabhushan Dr R A Mashelkar • Be Innovative • Not embark on beaten paths but traverse untrodden paths • Have Compassion • By creating therapeutics for poor that are available, affordable and accessible • Have Passion • To be best in the WORLD in terms of Quality of products, highest ethical standards and providing value for money

  17. Thank you.

More Related